Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures - Homepage
Triathlon Medical Ventures - Team
Triathlon Medical Ventures - Investment Focus
Triathlon Medical Ventures - Investment Strategy
Triathlon Medical Ventures - Investment Criteria
Contact Triathlon Medical Ventures - Evaluation Process
Triathlon Medical Ventures - Portfolio
Triathlon Medical Ventures - News
Triathlon Medical Ventures - Links
Contact Contact Triathlon Medical Ventures

Triathlon Medical Ventures

 

 

 

 

 

National Venture Capital Association 2008-2009 Member


Whether you're an entrepreneur or a venture capitalist, you'll find a warm welcome at Triathlon Medical Ventures. Prior to opening our doors in 2004, Triathlon's team has been investing in life science business opportunities for more than fifteen years. And we are also industry veterans, experienced at growing medical device and biotechnology companies from the inside out - as owners, directors and operational managers.

Triathlon Medical Ventures is a Midwest-based venture capital firm that invests exclusively in the life sciences. We provide equity capital to early and expansion stage companies with proprietary biomedical technology platforms or products addressing significant human healthcare needs.

We are geographically focused on early stage opportunities in the Midwest but will also invest in later stage companies nationwide. We are headquartered in Cincinnati, with offices and partners in Indianapolis, Louisville and St. Louis. The partners are industry veterans with extensive experience as both operational managers and venture capitalists.

We invite you now to explore these web pages and consider how Triathlon Medical Ventures might be the right partner for your investment opportunity.



RECENT NEWS

Click here for Triathlon Medical Ventures related videos on YouTube

November 3, 2009
Tolera Therapeutics Files IND Application for TOL101, Appoints O’Toole to Lead Clinical Operations


October 22, 2009
Endocyte Unveils Data on Ovarian Cancer Treatment (External Link)


October 15, 2009
Endocyte Announces Close of $26 Million Equity Financing


September 15, 2009
Akebia Announces Initiation of Phase 1 Clinical Study of AKB-6548


September 15, 2009
BioVEX Agrees SPA with the FDA for a Pivotal Phase III Study with OncoVEXGM-CSF in Head and Neck Cancer (External Link)


August 31, 2009
Akebia Appoints Victor Dzau, M.D. to Board of Directors


August 26, 2009
Endocyte Announces Achievement of Second Milestone in Collaboration with Bristol-Myers Squibb


July 28, 2009
Akebia Completes $16M Expansion of Series A Financing


July 1, 2009
Celleration Appoints Mark T. Wagner President and Chief Executive Officer (External Link)


 
 
Copyright © 2004 - Triathlon Medical Ventures - All Rights Reserved Web Site Credits Legal Notices & Privacy Policy